據報碧桂園(02007.HK)否認入局醬酒 指順朋酒業僅是核心聯盟企業並無股權聯繫
對於市傳碧桂園(02007.HK)近期已於仁懷市註冊成立貴州順朋酒業,正式入局醬酒行業,並於去年底拜訪多家仁懷當地酒廠洽談股權合作事宜,《每日經濟新聞》引述碧桂園回應指,有關消息與事實不符。
對於與順朋酒業是否存在聯繫,碧桂園指「順朋」是集團核心聯盟企業,業務覆蓋酒類營銷及戰略諮詢等企業服務,與集團並無股權關係。至於碧桂園創投是「順朋」項目的財務及戰略諮詢顧問,深度參與該創業企業的孵化。碧桂園創投過去參與投資寶醞和貝瑞甜心等酒類企業,目前在進一步做深度產業孵化的探索,白酒是其中一個重要賽道。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.